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INTRODUCTION 
 
 
Schizophrenia is a chronic and disabling mental disorder associated with abnormalities 
of brain structure and function (Lewis & Lieberman, 2000). It is characterized by the 
presence of delusions, hallucinations, disorganized speech and behaviour, with 
significant impairment in social or occupational functioning (DSM IV, 1994). More 
than 29 million people suffer from schizophrenia across the globe, of which 20 million 
live in developing or least developed countries (WHO, 1998). The diagnosis of 
schizophrenia is based on the patient's self-reported experiences and observed behavior 
as at present there is no laboratory test available for the diagnosis of schizophrenia. 
 
Schizophrenia is a treatable disorder with the treatment being more effective in its 
initial stage of illness. (WHO Mental Health Report, 1996). The first-line treatment for 
schizophrenia is typical or atypical antipsychotic medications and these can 
significantly alleviate the positive symptoms of psychosis. The second 
generation/atypical antipsychotics were developed with the hope that they would lead 
to improve the outcome for individual with schizophrenia in part by reducing both 
negative symptoms and the burden of extrapyramidal side effects. Although advantage 
for clozapine has been shown in many studies, it remains unclear whether the other 
second generation drugs have significant advantages in effectiveness and side effect 
profile over first generation neuroleptics medication when prescribed in appropriate 
doses. 
 
The meta-analysis by Davis et al 2003 and by Leucht et al, 2003 supported the 
advantage of second generation antipsychotic medications in its short term efficacy and 
relapse prevention. A meta-analysis by Geddes et al 2000 showed a modest advantage 
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for second generation antipsychotcs in efficacy and extrapyramidal side effects as 
compared to typical antipsychotic drugs. However according to the exhaustive reviews 
conducted by the Schizophrenia Patient Outcome Research Team (PORT) 2003 and 
multi-centric trials  CATIE (Clinical Antipsychotic Trial Intervention Effectiveness)  
funded by NIMH, have concluded there is no significant difference between newer 
agents as compared to the conventional agents, as far as effectiveness is concerned. The 
authors conclude that atypical antipsychotics are as effective as the conventional 
antipsychotics in the treatment of positive psychotic symptoms (Stein D. et al. 2005). 
However there is some evidence of superiority in the treatment of negative symptoms, 
mood symptoms, cognitive symptoms and enhanced quality of life by improving 
tolerability and adherence. Thus taken together, there is evidence to support the use of 
atypical antipsychotics (excluding Clozapine) as first line treatment agent for 
schizophrenia. While prescribing atypical antipsychotic medication as first line, 
clinicians need to be aware of and screen for newer antipsychotic induced adverse 
effects like weight gain, dyslipedemia, and impaired glucose tolerance 
hyperprolactinemia and to develop modules to intervene for these conditions. 
 
The antipsychotic drugs induced hyperprolactinemia and related morbidity is a 
neglected area in clinical practice as well as in research. This secondary 
hyperprolactinemia may lead to menstrual delay in females, disturbed sexual 
functioning in males and may cause reduced bone mineral density. (Sauer and Howard, 
2002). 
 
Clozapine, Quetiapine and Olanzapine are usually not associated with persistent 
hyperprolactinemia but may cause transient and mild prolactin elevation.  In contrast, 
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Risperidone and Amisulpride cause a marked and sustained increase in serum prolactin 
levels. In many studies, Risperidone, a widely prescribed atypical antipsychotic is 
known to show high propensity to cause hyperprolactinemia compared to typical and 
other atypical antipsychotic medications. 
 
Risperidone is an atypical antipsychotic, widely available, relatively inexpensive and 
extensively used in India.  
 
Hyperprolactinemia with antipsychotic medicines can influence bone mineral density. 
The studies which identified the reduced BMD in patients treated with antipsychotics 
are preliminary and suffer from small sample sizes and other methodological 
shortcomings (Haddad et al., 2003).  However, they are of concern and need to be 
studied in people on psychotropic medication.  
 
In this context the current study will estimate the prevalence of deficient bone mineral 
density and sexual dysfunction in a homogenous group of patients on long-term 
Risperidone treatment and estimate the correlation between them. As the relationship 
between antipsychotic use and its effect on BMD is complex, the correct interpretation 
of relation between Risperidone and BMD needs measurement of 25hydroxy vitamin-D 
levels, serum calcium, serum albumin, creatinine, serum prolactin and alkaline 
phosphates.  
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REVIEW OF LITERATURE 
 
 
Despite the fact that treatment with prolactin-increasing antipsychotic medication is 
regularly mentioned as a risk factor for osteoporosis, little is known about the 
prevalence and the degree of loss of bone mineral density in patients being treated with 
antipsychotics for psychotic disorders like schizophrenia (Halbreich et al 1995) and 
bipolar disorder. 
 
Osteoporosis is a disorder of increased bone fragility and low bone mass due to 
imbalance of osteoblastic and osteoclastic activities with a consequent increase in 
fracture risk (Johnston et al 1989).  
 
Osteoporosis can be classified into primary and secondary according to its etiology.  
The term “primary” osteoporosis refers to osteoporosis that results from the 
involutional loss associated with aging and in women, additional losses related to 
natural menopause. Osteoporosis that is caused or exacerbated by other disorders or 
medication exposures is referred to as “secondary” osteoporosis (Lane et al 2006). 
 
The physiology of bone formation, as well as the causes of osteoporosis is complex. In 
healthy individuals, bone remodelling is a constant, dynamic process, which has three 
primary functions: repair of micro-damage within the skeleton, maintenance of skeletal 
strength and regulation of the supply of calcium from the skeleton to maintain serum 
Calcium.  Several circulating hormones such as estrogens, androgens, vitamin D, 
parathyroid hormone, as well as local factors like insulin-like growth factor, 
transforming growth factor, parathyroid hormone related peptide, interleukins, 
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prostaglandins, tumour necrosis factor and osteoprotegrin ligands (Lindsay et al., 2001) 
regulate bone remodelling. 
 
Osteoporosis is a serious public health issue, affecting up to 1 in 2 women and 1 in 5 
men over the age of 50 years. The common osteoporotic fractures occur at the spine, 
wrist and hip (Richard Keen, 2007). Osteoporosis is a prevalent condition that affects 1 
in 4 women and 1 in 8 men in general population in Canada. (Clarene et al, 2004). One 
out of every two women and one in eight men over 50 years of age will have an 
osteoporosis-related fracture in their lifetime. The mortality rate associated with 
osteoporosis is substantial; for example, out of 80,000 men who suffer from a hip 
fracture each year, one-third die.  
 
Also, decreased BMD and resulting fractures place a significant financial burden on the 
health care system (NIH Osteoporosis Overview, 2000).  
 
Gold standard test to evaluate osteoporosis   
 
Bone strength is dependent on bone mineral density (BMD) and bone quality. BMD is 
the most readily accessible and quantifiable marker of bone strength and is often used 
as a predictor of fracture risk (Clarene H et al., 2004). Radiological measured bone 
mineral density (BMD) is an index of bone mass and is calculated by dividing the 
mineral content by the area or volume of bone scanned. Techniques commonly used are 
dual-energy X-ray absorptiometry and computed tomographic scanning.  
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Dual-Energy X-ray Absorptiometry (DXA) is at present considered to be the gold 
standard in measuring the BMD at the hip or spine. Additionally, it can also be used to 
measure the total amount of mineral in the whole skeleton or forearm. Hip BMD 
predicts risk of fractures at all other sites (11). It is usually unaffected by degenerative 
arthritis when compared with spine BMD. Spine BMD measures vertebrae L1 through 
L3 or L4. Vertebral bodies are largely made of trabecular bone that, because of its high 
ratio of remodeling surface to bone volume, is more sensitive to the effects of hormones 
and drugs than is cortical bone. Therefore, spine BMD tends to change, more in 
response to some medical conditions, such as glucocorticoid excess, and to treatments 
than does BMD of other sites. On the other hand, standard spine BMD, measured in the 
anteroposterior direction, includes mineral in the posterior elements and facet joints as 
well as the abdominal aorta, none of which contribute to the strength of the vertebral 
body. Consequently, spine BMD is increased by degenerative arthritis and, for this 
reason, may increase in some individuals after the age of 65 years rather than decrease 
when compared to other BMD measurements.  
T and Z scores 
Densitometers report T and Z scores that are specific to the patient's sex, and some 
manufacturers report values compared with those of patients of the same race. A Z 
score is the number of Standard Deviation (SD) s below or above the mean BMD value 
for people of the same age. A Z score of 0 means that the patient has a value that is 
exactly at the mean for her age. A Z score of minus 2.0 means that the patient has a 
BMD at that site, by that method, that is 2 SDs below the mean BMD value of others 
the same age. 
  
 13
In contrast, a T score is the number of SDs (standard deviations) below the mean BMD 
for young (25- to 45-year-old) adults. A T score of 0 means that the patient has a BMD 
value that is exactly at the mean for young adults. Both of these variables rely on SD 
for the measurement. An SD represents the normal variability in a measurement in a 
young normal population—the distance between the 5th and 95th percentile of a group 
covers about 4 SDs. Standard deviations vary from technique to technique and among 
various reference populations that are used to define normal values. For hip and spine 
BMD, 1 SD corresponds to about 10% to 15% of the mean value for young adults. 
  
A T score of minus 2.5 means that the patient has a BMD value at that site and by that 
method that is 2.5 SDs below the mean. Because BMD declines with age, T scores are 
consistently lower than Z scores after about age 40 years, and the difference increases 
with age. Since the relationship between decreasing bone density and increasing risk of 
fractures is a continuous one, there is no threshold or cutoff value to distinguish low- 
and high-risk people.  
 
 WHO criteria for Osteoporosis & Osteopenia 
 The World Health Organization has defined osteoporosis as a bone density with a T 
score of minus 2.5 or less and osteopenia as a bone density T score between minus1.0 
and minus 2.5. This cut-off has no inherent biological meaning as it was created to 
allow comparisons of the prevalence of osteoporosis in different countries and was not 
intended (initially to be used) to make treatment decisions. 
   
The diagnosis of osteoporosis according to BMD can be confusing at times, if 2 or 
more sites are measured, patients will sometimes have a T score of minus 2.5 or less 
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and so-called osteoporosis at one site and above that level at other sites (14). Some 
experts and guidelines  
 
Consider a T score at or less than minus 2.5 at the femoral neck or total hip to be the 
gold standard for the diagnosis of osteoporosis. Others prefer to diagnose osteoporosis 
if the T score at either the hip or spine is at or below minus 2.5; the latter approach 
designates more women as having osteoporosis who will, on average, have a somewhat 
lower risk of fracture. The upper cutoff, a T score of minus 1.0, was also chosen 
arbitrarily to indicate women whose bone density was below normal for young adults.  
 
The BMD value can be used to predict the risk of later fractures and the risk of fracture 
approximately doubles with each standard deviation of decrease in age-adjusted mean 
BMD (Genant et al., 1999). 
 
Mechanism of bone loss    
 
Hyperprolactinaemia is associated with reduced bone mineral density. This is mediated 
by the inhibition exerted by dopamine on the hypothalamic–pituitary–gonadal axis and 
the resulting hypogonadism.  
 
In women, a chronic elevation of prolactin levels induces inhibition of the 
hypothalamic secretion of luteinizing hormone-releasing hormone. This, in turn, lowers 
levels of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which 
regulate gonadal steroid production and release. The principle gonadal steroid, estrogen 
inhibits osteoclasts, which are responsible for bone resorption, and stimulate osteoblasts 
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that mediate bone formation. Hence, estrogen deficiency may reduce bone density in 
women by increasing osteoclastic activity and reducing osteoblastic formation. 
(Halbreich et al., 2003). Estrogen may also play an important role in determining the 
life span of bone cells by controlling the rate of apoptosis. Hence, in low estrogen 
states, the lifespan of osteoblasts may be decreased and the longevity of osteoclasts 
increased. In adolescents and young women, sustained production of estrogen is 
essential for the maintenance of bone mass and persistent estrogen deficiency 
secondary to prolactin elevation causes significant bone loss. (Coss et al, 2000). 
 
In males, testosterone deficiency has been shown to be associated with osteopenia 
(Halbreich U, 1996). 
 
Other minor mechanisms are mentioned in literature. Elevated levels of parathyroid 
hormone (PTH)-related peptide (PTHrP), secondary to hyper- prolactinemia, can cause 
bone mineral density changes (Raisz et al., 2003). Reduced estrogen can influence the 
activity of interleukins, which are known to influence bone dynamic homeostasis 
(Halbreich et al., 1996). 
 
 16
Risk factors for low MBD:  
 
 
Major risk factors for low BMD Minor risk factors for low BMD 
Alcohol and drug abuse  Rheumatoid arthritis 
Heavy smoking  Past history of clinical hyperthyroidism 
Immobility Chronic anticonvulsant therapy 
Reduced exposure to sunshine resulting 
in vitamin D def 
Low dietary calcium intake 
 
Polydipsia and dietary deficiency Excessive caffeine intake 
Systemic glucocorticoid Rx >3/12 Chronic heparin therapy 
Vertebral compression fracture Weight loss >10% of weight at age 25 
Fragility fracture after age 40  Body Weight <57kg 
 
(Clarene Ho et al 2004; Cantor-Graae E  et al 2001; Kavanagh DJ, 2002 and  DeLeon J 1994)  
 
 
Prolactin physiology and regulation 
 
Prolactin is secreted in a pulsatile manner by the anterior pituitary gland. There are 13 
or 14 peaks per day, with an inter-pulse interval of about 95 min. The upper limit of 
unstipulated prolactine levels in men and women varies between laboratories, ranging 
between 350 mU/l and 550 m U/l. (Veldhuis and Johnson, 1988). Hypothalamic 
dopamine is the predominant prolactin-inhibiting factor. Released into the portal 
hypophyseal circulation it binds to D2 receptors on lactotroph cells. Stimulation of D2 
receptors has inhibitory effects on prolactin gene transcription, synthesis and release.  
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Serotonin (5-HT) has a stimulatory role in prolactin regulation mediated through 5-
HT1A and 5-HT2 receptors. Estrogens can modulate prolactin secretion by inhibiting 
hypothalamic dopamine synthesis, reducing the number of pituitary D2 receptors, 
enhancing prolactin gene transcription and synthesis.  
 
The hyperprolactemia can be clinically   manifested as   amenorrhea, cessation of 
normal cyclic ovarian function in female and hypospermatogenesis in male (Petty, 
1999).  
 
Literature on Hyperprolactemia and its secondary complication 
 
In women with pituitary adenoma and hyperprolactinemia had 17% decrease in cortical 
bone and 25% of trabecular bone. (Klibanski, 1980; Cann, 1984; Koppelman, 1984; 
Schlechte, 1987). In men hyperprolactinemia resulting from prolactin-secreting 
pituitary tumours also caused hypogonadism and osteoporosis. Greenspan 
demonstrated significant loss of BMD in forearm and vertebrae in men with 
hyperprolactinemia (Greenspan et al, 1986). 
 
Hyperprolactinemia and Amenorrhea  
 
Hyperprolactinemia hypogonadal women with secondary amenorrhea resulting from 
low estrogen production were found to have significantly lower BMD than 
hyperprolactinemic women who maintained sufficient estrogen levels to retain menses. 
The duration of amenorrhea was positively associated with severity of BMD loss.  
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Forty-two percent of hyperprolactinemia women who remained amenorrhic for a period 
of 1.7 + 0.2 years exhibited BMD loss more than two standard deviations below the 
control mean   (Biller et al., 1991). 
 
Antipsychotic induced Hyperprolactinemia 
 
All conventional antipsychotic drugs cause dose dependent blockade of D2 receptors 
on lactotroph cells removing the main inhibitory influence on prolactin level and 
causing hyperprolactinemia. This is defined as a level above the upper limit of normal 
(>24.20 ng/ml for females and >18.77 ng/ml for males). Elevation of prolactin levels 
occurs within a few hours of treatment initiation and persists with long-term treatment. 
(Smith, 2002). Women have significantly greater prolactin elevations than men during 
chronic antipsychotic treatment with equivalent doses. (Wode-Helgodt et al., 1977; 
Kuruvilla et al., 1992; Smith et al., 2002). 
 
When oral antipsychotic therapy is discontinued, baseline prolactin levels may take up 
to 3 weeks to return to the normal range depending on the half-life of the drug and its 
metabolites as well as storage in fatty tissues (Turkington, 1972). In the case of depot 
medication, normalization may take as long as 4-6 months (Wistedt B., Wiles D. & 
Kolakowska T., 1981).  
 
Recent research in the field of  antipsychotic induced osteoporosis 
 
In a cross-sectional study of 402 (147 female + 255 males) patients in whom prolactin 
levels were measured after a minimum of 3 months' treatment with conventional anti-
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psychotics or Risperidone (Kinon and Glimor, 2001), the prevalence of 
hyperprolactinemia among women of reproductive age (n=90) was 65.6% (mean serum 
prolactin=69.0 ng/ml), and among postmenopausal women (n=51), it was 45.1% (mean 
serum PRL=49.0 ng/ml). The prevalence of hyperprolactinemia across all males 
(n=255) was 42.4% (mean serum PRL= 32.4 ng/ml). The prevalence of 
hyperprolactinemia among females taking Risperidon (N=42) was 88% versus 47.6% 
of those taking conventional antipsychotic drugs (N=105), with 48% of those females 
of reproductive age on Risperidone experiencing abnormal menstrual cycles (secondary 
amenorrhea, oligomenorrhea, or polymenorrhea). Thus hyperprolactemia was more in 
female (as compared to male) with Risperidone (as compared to conventional 
antipsychotics) in the reproductive age group (than post menopausal group).  
 
Antidepressants with serotonergic activity, including selective serotonin reuptake 
inhibitors, monoamine oxidase inhibitors and some Tricyclic antidepressants, anti 
epileptic mood stabilizer can cause modest elevations of prolactin levels.  
When these drugs are given as monotherapy patients have reported symptoms of 
hyperprolactinemia, but such reports are rare. In patients whose prolactin secretion is 
already stimulated by antipsychotic drugs, SSRI or Mood stabilizer have the potential 
to elevate prolactin levels above the threshold for ovarian dysfunction and 
galactorrhoea or to worsen existing symptoms.  
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Studies of bone density in psychiatric patients 
 
In women exposed to antipsychotic medication bone density has been assessed in few 
studies.  
 
Ataya’s study assessed only ten premenopausal women who had been treated with 
antipsychotic drugs for an average of 10 years and had developed amenorrhea or 
oligomenorrhoea. DEXA Scan was taken for whole spine and head and neck of femur. 
Data was compared with age and gender related normative values from a large 
database. 
The study showed BMD was reduced by about 12% at three sites of the femur, but not 
in the spine. Ataya et al (1988) talk about the antipsychotics induced bone mineral 
density changes in premenopausal patients who are clinically symptomatic. However 
this was a very small   sample size and clinically asymptomatic patient who might have 
BMD changes were not included. 
 
Halbreich et al (1995) found significantly reduced BMD values in the lumbar spine in a 
group of women treated with antipsychotic, antidepressant and mood-stabilizing 
medication, either alone or in combination. The finding of this study suggested for the 
first time loss of bone mineral density in the lumbar spine. However the limitation of 
the study was the heterogeneous composition of the study group. 
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Hummer et al (2005) in a cross-sectional study used dual x-ray absorptiometry to 
determine bone mineral density of 75 inpatients and outpatients suffering from 
schizophrenia. All patients had been treated with antipsychotics for at least 1 year, and 
only patients between the ages of 19 and 50 were studied to exclude patients with age-
related idiopathic osteoporosis. In men, but not women, with schizophrenia, bone 
mineral density was significantly lower than normal in the lumbar region. A 
comparison of loss of bone mineral density in male and female patients showed 
significant differences between the sexes. Bone mineral density showed a negative 
correlation with negative symptoms and Positive and Negative Syndrome Scale total 
score and a positive correlation with 25-hydroxy-vitamin D3 levels and body mass 
index in male patients.  
 
In female patients, a positive correlation between body mass index and bone mineral 
density was found. Exposure to prolactin-increasing antipsychotic was not related to 
bone mineral density. 
  
In a study comparing the BMD changes between prolactin sparing and prolactin rising 
antipsychotic (O’Keane, Meaney et al., 2005) 64% of patients on prolactin rising 
antipsychotic had decreased BMD. 
 
In a review of bone mineral changes in male schizophrenic patients estimated 
prevalence of osteopenia ranging from 40-72% compared to controls (Jonathan, Meyer 
David et al., 2006). 
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Meaney and O’Keane, (2007) on an interventional study compared BMD alterations 
over a period of 1 year in patients maintained on either prolactin-raising (e.g. 
risperidone, amisulpride or depot anti-psychotics) or prolactin-sparing (Olanzapine) 
anti-psychotics. Pre-menopausal females (n=38) with a diagnosis of schizophrenia, who 
had received exclusively either prolactin-raising (n=25) or prolactin-sparing (n=13) 
anti-psychotics during their treatment history, had clinical, endocrine and bone marker 
assessments performed at baseline and every 3 months for a period of 1 year. BMD was 
measured by DXA scan at baseline and at 1-year follow-up. Patients from both groups 
either received specific interventions (n=16) or no interventions (n=16) to improve 
bone density. Women taking prolactin-raising anti-psychotics and not receiving specific 
interventions to improve bone density had evidence of ongoing bone demineralization 
over a year; whereas women taking prolactin-sparing anti-psychotic drugs had a modest 
overall increase in BMD. This is the only interventional study available in literature as 
per our knowledge.  
 
Role of Vitamin D status in relation to BMD 
 
Bone mineral density is also influenced by vitamin D status. Bone mineral loss in 
vitamin D insuffiency is caused by more than one mechanism. The secondary 
hyperpathyroidism resulting from low vitamin D has a detrimental effect on bone 
mineral density. Low serum 25 (OH) vitamin D concentration is the hallmark of 
vitamin deficiency. A level of more than 30 ng/ml is considered adequate (Holick et al, 
1995). The Indian subcontinent, situated between 8.4_ N and 37.6_ N latitude, has 
adequate sunshine and UV B rays (290–315 nm) reaching the earth’s surface 
throughout the year (40). Therefore, it has been presumed that Indians are vitamin D 
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sufficient. Goswami R et al in a study on healthy Indians has suggested a high 
prevalence of subnormal 25 (OH) D concentrations. It has been demonstrated in similar 
other studies from India (Paul et al 2008, Goswami et al 2008)  
 
Role of Vitamin D status in relation to psychiatric morbidity 
 
Vitamin D not only is integral to maintaining bone health, but it also plays a role in 
several other biochemical mechanisms within the human body. 15 years ago, Professor 
Walter E. one of the great pioneers in vitamin D research, predicted a substantial role 
for both bright light and vitamin D in psychiatry. In 1999, study conducted by Hollis B 
showed that 100,000 IU of vitamin D given as a one time oral dose improved 
depression scales better than light therapy in a small group of patients with seasonal 
affective disorder. German authors also found healthy controls had an average serum 
25(OH) D of 46 ng/L while depressed subjects had 37 ng/L. Most recently, a direct 
correlation was found between 25(OH)D levels and mental health scores in a group of 
healthy, elderly adults, although 1,000 IU of cholecalciferol per day did not improve 
mental health scores of these highly-functional subjects and this may be attributed to 
inadequate dosing of Vitamin D( less than 2000IU per day  The probable mechanism 
related to vitamin D  supplementation and improvement of depression is that vitaminD 
rapidly increases the in-vitro genetic expression of tyrosine hydroxylase (the rate-
limitin enzyme for the catecholamine biosynthesis) by threefold. Vitamin D also 
increases the expression of tyrosine hydroxylase gene in adrenal medullary cells.  
 
Evidence suggests that vitamin D may help mood but that evidence is not conclusive. 
The above positive studies  used vitamin D to treat seasonal affective disorder, not 
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major depression. There is enough biological evidence to suggest an important role for 
vitamin D in brain development and function. However, direct effects of vitamin D 
inadequacy on cognition/ behaviour in human or rodent systems appear to be subtle. 
 
The vitamin D hypothesis of schizophrenia is a recent concept bringing together old 
observations on environmental risk factors and new findings on the 
neurodevelopmental effects of vitamin D. Candidate genes related to the vitamin D 
endocrine system have not yet been fully explored for this purpose. The coexistence of 
vitamin-D-dependent-rickets type II with alopecia (VDDR IIA) and different forms of 
psychosis in the same inbred family has provided us with an opportunity to investigate 
the presumed relationship.  
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AIMS AND OBJECTIVES OF STUDY 
 
 
The aims of the study: 
 
1. To estimate the prevalence of osteoporosis in patients taking Risperidone for 
more than 1 year. 
 
2. To study the prevalence of hyperprolactinemia and to estimate the association 
between hyperprolactinemia with sexual dysfunction. 
 
3. To study the drug dose and various bone mineral parameters and their influence 
on BMD. 
 
4. To estimate the association between decreased BMD and erectile dysfunction in 
males or amenorrhea in females. 
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METHODS AND METHODOLOGY 
 
Subjects for screening were be obtained by three methods. First, charts of all 
outpatients attending the psychiatry review clinics – Monday to Thursday, 2 to 5 pm - 
were checked at the MRD, by the principal investigator (PI), before distribution. 250 to 
350 patients are seen on each day. Second, all clinical staff were informed of the study 
and requested to refer suitable subjects. Third, all inpatients will be screened. Screening 
was conducted on the basis of recorded data from the chart. 
 
Screening would include adults between the ages of 18 and 50 years, and who have 
been on Risperidone as the sole antipsychotic, for at least 12 months. Exclusion criteria 
included the drugs other than Risperidone, which cause hyperprolactemia and the 
conditions known to be associated with osteoporosis, the outcome of interest. 
 
The PI, in the appropriate language, and using lay terms, explained the nature of the 
study to the potential subject and the relative, when present. The format for this is 
attached as Appendix I. The PI speaks English, Hindi, Bengali, Oriya and Tamil with 
sufficient fluency. 
 
Written informed consent was obtained.  
 
The bone mineral density of the subject was assessed with dual X-ray Absorptiometry 
(DXA). This was done at CMCH and the PI made the appointment at the patient’s 
convenience. 
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The interpretation of the findings and the diagnosis and grading of osteoporosis was 
done by the staff of the department of endocrinology. They did not have access to the 
clinical details of interest in the study. 
 
Data on socio-demographic variables, medication details and putative proxy clinical 
indicators (amennorhea in women and erectile dysfunction in men) were also be 
obtained using a specially designed proforma.  
 
64 subjects will be recruited into the study. 
 
The biostatistician has been consulted. Sample size calculation has been done on the 
basis of prevalence reported in previous studies.  
 
Inclusion Criteria 
 
• Age between 18 and 45 years. 
• Patient on Risperidone as the only antipsychotic drug for at least for 12 months  
• Subjects giving written informed consent  
 
Exclusion Criteria 
 
• Patients with Alcohol dependence syndrome or Anorexia Nervosa.  
• Patients on combination of antipsychotic medications.  
• Patients on other drugs which can cause hyperprolactinaemia, (Sodium 
Valproate, Carbamazepine, Tricyclic antidepressants, Specific Serotonin 
Reuptake Inhibitors, and oral contraceptive pills) 
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• Non-ambulant patients. 
• Pregnant or lactating women.  
 
Evaluation 
 
Patients who fulfilled the eligibility criteria were selected for the study. The following 
parameters were assessed. 
 
1. Clinical and demographic profile  
 
– All patients were asked for their demographic details, duration of untreated psychosis, 
past history of exposure to antipsychotic medication, duration of treatment with 
risperidone, and other psychotropic drug given with risperidone, history of bone pains, 
fractures and proximal muscle weakness.  From the patient charts, the details regarding 
the Axis –I diagnosis and other co-morbid conditions were obtained.  
 
2. Biochemistry 
 
The following biochemical parameters were assessed. 
         Fasting blood samples were collected for the assessment of serum calcium, 
phosphate, alkaline phosphatase, albumin, creatinine and 25 hydroxy Vitamin D.       
These parameters were measured in HITACHI 911 model auto analyzer, which is a 
fully automated and computerized microanalyser (Boehringer Mannheim). 
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Calcium  
 
– Calcium forms a violet complex with O-cresolphthalein complexone in an alkaline 
medium.  The violet colour medium is measured photometrically at 570 nm.           
[Normal range:  8.3 to 10.5 mg per deciliter]. 
 
Phosphate  
 
– Inorganic phosphorus reacts with ammonium molybdate in sulphuric acid solution to 
form ammonium phospho molybdate, which is blue in colour and measured at 340 nm 
[Normal range: 2.5 to 5.3 mg per deciliter]. 
 
Alkaline Phosphatase 
 
– The activity is measured kinetically by the formation of paranitrophenol from 
paranitrophenylphosphate.  Alkaline phosphatase hydrolyses p-nitrophenylphosphate to 
paranitrophenol, which is measured photometrically at 415 nm [Normal range:  40 – 
125 U per litre]. 
 
Creatinine  
 
– Creatinine forms a coloured complex with picrate in alkaline solution.  The rate of 
formation of this complex is measured at 505 nm.  [Normal range: 0.5 – 1.4 mg per 
deciliter]. 
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Albumin 
 
When bound with bromocresol green, albumin exhibits change in absorbance at 600 
nm, which is the result of formation of a green coloured albumin dye complex.  The 
intensity of the colour is proportionate to the concentration of   Albumin [Normal 
range:  3.5 – 5.0 gm per deciliter] 
 
25 OH vitamin D (vitamin D) 
 
It was measured using electrochemiluminiscence method (Roche diagnostic, 
Indianapolis, US). This assay uses a polyclonal antibody directed against 25-OH 
vitamin D3.  The analytical sensitivity is 4ng/ml.  It has a coefficient of variation of 6.6 
to 9.9% at low and high levels. Vitamin D levels more than 30 ng/ml was considered 
sufficient. Levels between 10-30ng/ml was considered insufficient and levels <10ng/ml 
was considered vitamin D deficient. 
 
Prolactin 
 
Serum prolactin was measured using chemi luminescent assay in Immulite 2000 
Hyperprolactinemia was defined as the level of serum prolactin of >24.20 ng/ml for 
females and >18.77 ng/ml for males. This assay had analytical sensitivity of 0.16% 
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3. Bone densitometry 
 
DXA scan: BMD was assessed by using the Hologic Machine (QDR 4500; Hologic, 
Inc., Waltham, MA, USA) at lumbar spine and femoral neck. Reference population was 
normal Caucasians (manufacturer’s database). Precision was 2 percent at both the 
measured sites (spine and neck of femur). 
 
SAMPLE SIZE CALCULATION 
Sample size was calculated using the formula:  n=4pq/d2   A sample size of 64 was 
required to find a prevalence of 20% ± 10 at 95% confidence 
 
STATISTICS 
 
An Independent T test was used to compare the means of two continuous variables if 
they were normally distributed and nonparametric tests were used if their distribution 
were not normal. Chi square or Fisher exact test was used when variables were 
categorical. A correlation between 2 continuous variables was done using Pearson’s 
correlation. Logistic regression was done to assess the effect of multiple variables on 
bone mineral density and osteoporosis. Statistical analysis was done using the SPSS 11 
software package 
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RESULT 
 
Table 1: Demographic data 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Variables Subgroups Mean (SD) 
Age groups 18-45 29.45 (6.56) 
Gender 
 
Female 
Male 
32 (49.2%) 
33  (50.8%) 
Religion 
 
Hindu 
Christian 
Muslim  
60 (92.3%) 
4   (6.1%) 
1  (1.5%) 
Diagnosis 
 
 
Schizophrenia 
Psychotic Bipolar 
Schizoaffective 
Acute psychosis 
38 (58.5%) 
23 (35.4%) 
2    (3.1%) 
2    (3.1%) 
Past history of 
antipsychotic 
exposure 
P/H of ASD exposure 
Nil 
18 (27.7%) 
47 (72.3%) 
Current 
combination of 
treatment 
Only on risperidone 
Risp+Pacitine 
Risp+Lithium 
Risp+LI+ Pacitine 
Risp+BZD 
Risp+Li+BZD 
18 (27.7%) 
27 41.5% 
11(16.9%) 
5 (7.7%) 
3(4.6%) 
1(1.5%) 
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The demographic data is explained in Table 1. Sixty five patients with mean age of 
29.45 year (6.56) fulfilled the inclusion criteria and were included in the study after 
obtaining informed consent. 60 (92.3%) of the subjects were Hindus and 5 (7.7%) 
belonged to Muslim or Christian community. An ICD 10 diagnostic criterion for 
schizophrenia was met by 38 (58.5%). The remainders were diagnosed to have either 
psychotic bipolar disorder (35.4%) or acute psychosis (3.1%) or schizoaffective 
disorder (3.1%). 
 
Within the total subject group, 18 (27.7%) of the patients were only on Risperidone 
where as the others were on the combination of Risperidone with other medications - 
Risperidone with Lithium were 11 (16.9%); Risperidone plus Trihexyphenidyl 27 
(41.5%); risperidone plus Lithium with Trihexyphenidyl 5 (7.7%) and Risperidone with 
benzodiazepine 4 (6.1%).  
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Table 2: Comparison of Demographic and clinical data in both genders 
 
  
Variables Total N=65 Female N=32 Male N=33 P value 
Age  
29.45 SD 6.56 
 
28.84 SD 6.59 30.06 SD 
6.53 
0.458 
Religion 
Hindu 60 (92.3%) 
Others 05 (07.7%) 
28 (87.5% ) 
04 (12.5% ) 
32 (97.0%) 
01 (03.0%) 
0.197 
Occupation  
Job 54 (83.1%) 
Nil 11(16.9%) 
28 (87.5%) 
04 (12.5%) 
26 (78.8%) 
07 (21.2%) 
0.511 
Diagnosis  
Schiz: 38  (58.5%) 
Bpad/scizoaff: 27(41.6%) 
21 (65.6%) 
11 (34.4%) 
17 (51.5%) 
16 (48.5%) 
0.450 
Comorbid axis I 
Present: 3(100%) 
Nil                  0 
32 (100%) 
00 
30 (91.9%) 
03 (09.1%) 
0.238 
Past H/O 
antipsychotic 
Present: 18 (27.7%) 
Nil: 47 (72.3%) 
10 (31.3%) 
22 (68.8%) 
8 (24.3%) 
25(75.7%) 
0.587 
Dose of 
risperidone 
Dose of risperidone 0-4mg 
Dose of risperidone 4.5-
10.5mg 
17 (53.1%) 
15 (46.9%) 
19 (57.6%) 
14 (42.4%) 
0.805 
 
 
Table 2 shows that this group consists of thirty two women (49.2%) with mean age of 
28.84 (6.59) and   thirty three men (50.8%) with mean age of 30.06 (6.53) There was no 
significant difference between the male and female groups in terms of religion, 
occupation, co-morbid Axis -I diagnosis or past history of exposure to other 
antipsychotics.  
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Table3: Comparision of clinical profile across male and female groups 
 
 
 
Table 3   shows comparison between men and women on additional clinical variables.  
It was found that there was no significant difference in terms of age of onset of 
psychotic illness, duration of untreated psychosis, average dose and mean duration of 
treatment with risperidone.   
 
 
 
 
Variables Mean with SD Female N=33 Male N=32 Odd ratio/P value 
Age 29.45 (6.56) 28.84 (6.59) 30.06 (6.53) 0.458 
Age of onset of 
psychosis 
24.38 (5.51) 24.31 (5.48) 24.45 (5.63) 0.92 
Duration of 
untreated 
psychosis 
7.43 (12.048) 7.00 (10.68) 7.85 (13.39) 0.779 
Average Dose 
of Risperidone 
for last 1 year 
4.68 (1.778) 4.53 (1.79) 4.82 (1.77) 0.520 
Duration of 
treatment with 
Risperidone 
32.63 (21.468) 29.94 (17.01) 
 
35.24 (25.04) 
 
0.323 
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The biochemical parameters were compared amongst the sub groups of both female and 
male and it was observed that there was no significant difference between the male and 
female groups in terms of mean level of serum alkaline phosphatase, serum calcium, 
phosphorous or serum vitamin D. However, there was a significant difference between 
female and male groups in terms of body mass index (p =0.026) and serum prolactin 
level p< 0.0001.  
 
 
 
 
 
 
 
 
 
 
Table 4.1: Comparison of the biochemical variables across gender  
Variables Female mean (SD) Male mean (SD) P value 
Alk phos 84.12 (22.63) 81.39 (26.42) 0.656 
Phosphorus  
 
3.66 (0.64) 3.74 (0 .47) 0.583 
BMI 27.7 (5.7) 24.49 (5.22) 0.026 
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Table 4.2: Comparison of Hyperprolactinemia and Vitamin D deficiency across gender  
 
 
Biochemical level Female N=33 Male N=32 P value Odd ratio 
Hyperprolactemia 27 (84.4%) 26 (78.8%) 
Normal Prolactin 05 (15.6%) 07 (21.2%) 
0.103 
1.454(0.409-
5.165) 
Normal Vitamin D 0 (0%) 03 (9.30%) 
Either Vitamin D 
deficient or 
insufficiency  
31(100%) 29 (91.7%) 
0.24 2.47 (0.82-7.46) 
 
 
Hyperprolactinemia is defined as the level of serum prolactine of >24.20 ng/ml for 
females and >18.77 ng/ml for males. In this study, the prevalence of Hyperprolactemia 
in female was found to be 27 (84.4%) and in males 26 (78.8%). The odds ratio 
estimation showed female were 1.4 times at more risk of Hyperprolactinemia as 
compared to males. 
 
Out of the 65 subjects taken in to the study, 2 women and one man (4.6%) were missed 
out on Vitamin D level assessment. Of the rest, 60 (92.3%) had vitamin D deficiency 
(n=20, 30.8) or vitamin D insufficiency (n=40, 61.5%). Only 2(3.1%) of the subjects 
had normal serum vitamin D level (>30 ng/ml). The comparison   between the gender 
groups in relation to Vitamin D deficiency and Vitamin D non-deficiency did not show 
any significant difference.  
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Bone mineral density measure in neck of the femur 
 
 
 40% of subjects had BMD abnormalities in the neck of femur. 2 subjects had 
osteoporosis (3.09%) and 24 (36.91%) had osteopenia. Both subjects with osteoporosis 
were male. Overall, 14 (42.5%) of the men and 12 (37.5%) of the women had reduced 
bone mineral density values at neck of the femur. 
 
Table 5: Clinical and demographic parameters compared for neck of the femur  
 
 
Variables N (%) 
Normal BMD 
N =39 
Osteoporosis/peni
a N=26 
P value 
Gender 
Female:   32 (49.2%) 
Male:  33 (50.8%) 
20(51.3%) 
19 (48.7%) 
12 (46.2%) 
14 (53..8%) 
0.801 
Diagnosis of 
the patient 
Schizophrenia:  38  (58.5%) 
BPAD /SA dis:  27  (41.6%) 
24 (61.5%) 
15 (38.5%) 
14 (53.8%) 
12 (46.2%) 
0.612 
Co –morbid 
Axis I diag. 
No Comorbid dis: 55 (84.6%) 
Co morbid cond: 10 (15.4%) 
33 (84.6%) 
6 (15.4%) 
22 (84.6%) 
4 (15.4%) 
0.631 
Occupation 
Nil job:  11 (16.9%) 
Working:  54 (83.1%)  
7 (17.9%) 
32 (82.1%) 
4 (15.4%) 
22 (84.6%) 
1.00 
Other 
medication  
No other med:  18 (27.7%) 
Other medication: 47 (72.3%) 
13 (33.3%) 
26 (66.7%) 
5 (19.2%) 
21 (88.8%) 
0.266 
 
 
The above table shows that there was no statistical significance difference between 
normal BMD group and abnormal BMD group in   terms of gender, occupation, Axis I 
diagnosis, exposure to other antipsychotic medications in the past and other co-morbid 
conditions.  
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Table 6: Bio chemical parameters compared for BMD at the neck of the femur 
 
 
 
Variables Mean with SD 
Normal BMD 
N =39 
Osteoporosis/penia 
N=26 
P value 
Prolactine level 46.73 (32.51) 43.67  (31.13) 49.74 (33.90) 0.460 
Serum calcium 8.57 (0.315) 8.64 (0.32) 8.51 (0.31) 0.119 
Vitamin D 15.18 (8.19) 16.83 (9.23) 13.54 (0.15) 0.133 
Serum alkaline 
phosphatase 
83.06 (50.25) 81.43 (21.08) 84.69 (29.17) 
 
0.603 
Serum Phosphorous 3.66 (0.52) 3.86 (0.55) 3.46 (0.48) 0.004 
 
 
 
On comparison, the biochemical parameters in normal BMD and abnormal BMD group 
did not show significant difference. The biochemical parameters checked were Serum 
Prolactine, Calcium, Phosphorous, Vitamin D and serum Alk phosphatase. 
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Table 7: Prolactine value compared across the abnormal and normal BMD groups 
at femur neck  
  
 
 
Variable N=65 
Abnormal 
BMD N=26 
in neck of 
the femur 
Normal 
BMD 
N=39 in 
neck of the 
femur 
P 
value 
Odd ratio 
with CI with 
risk 
Hyperprolactinemia 53 (81.5%) 23 (88.5%) 30 (76.9%) 
Normal 12 (18.5%) 03 (11.5%) 09 (23.1%) 
0.334 
2.3 (0.559- 
9.468) 
Vitamin D 
deficiency 
20 (32.3%) 9 (34.6%) 11 (30.6%) 
Normal/insufficient 
Vitamin D level 
42(67.7%) 17 (65.4%) 25 (69.4%) 
0.736 
0.831 (0.284 -
2.43) 
 
 
Comparative analysis between the subject with normal BMD and abnormal BMD 
group at femur neck in respect to hyperprolactinemia and serum vitamin levels did not 
yield significant difference.  
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Bone mineral density measure in Lumbar spine 
 
 
29 (44.7%) subjects had BMD abnormalities in the lumbar spine. 9(13.8%) had 
osteoporosis, and 20(30.9%) had osteopenia.  Of the 9 with osteoporosis, 7 were men 
and 2 were women. 
Table 8: Demographic and Clinical parameters compared for lumbar spine 
  
 
Variables N (%) 
Normal BMD 
N =36 
Osteoporosis/
penia N=29 
P 
value 
OR CI 
Gender 
Female: 32 (49.2%) 
Male:  33 (50.8%) 
20 (62.5%) 
15 (46.9%) 
12 (37.5%) 
17 (53.2%) 
0.315 
0.529 (0.195-
1.435) 
Diagnosis 
of the 
patient 
 Schizophrenia: 38  
(58.5%) 
BPAD/SA disorder: 27  
(41.6%) 
 
21 (56.8%) 
14 (51.9%) 
 
16 (43.2%) 
13 (48.1%) 
 
 
0.697 
 
0.821 (0.303-
2.22) 
Religion 
Hindu 
Others 
31(51.7%) 
4 (100.0%) 
29 (48.3%) 
0 
0.060 0.51 (0.40- 
0.66) 
Co-morbid 
axis I diag. 
 No Co morbid 
disorder:  55 (84.6 %) 
Co morbid conditions: 
10 (15.4%) 
27 (50.0%) 
08 (80%) 
27 (50.0%) 
02(20.%) 
0.080 4 (0.77-20.59) 
Occupation 
Nil  job: 11 (16.9%) 
Working: 54 (83.1%) 
6 (54.5%) 
29 (54.5%) 
5 (45.4%) 
24 (45.4%) 
0.992 
1.007 (0.27-
3.71) 
Other 
medication  
No other med:  18 
(27.7%) 
Other medication: 47 
(72.3%) 
09(50.0%) 
26(56.7%) 
 
09 (50.0%) 
20 (43.3%)
0.637 
 
1.3 (0.436- 
3.87) 
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Table 8 looks at the differences between the normal BMD group and the osteopenic/ 
osteoporotic group in terms of gender, remove makes no sense, occupation, Axis I 
diagnosis exposure of other antipsychotic medication in the past and other co morbid 
conditions. No statistical difference was seen. 
 
Table 9: Bio chemical parameters compared for lumbar spine 
   
 
 
Variables Mean with SD Normal BMD N =34 
Osteoporosis
/penia N=29 P value 
Prolactine level 46.73 (32.51) 49.30 (31.93) 43.15 (33.83) 0.460 
Serum calcium 8.57 (0.315) 8.60 (0.35) 8.58 (0.29) 0.826 
Vitamin D 15.18 (8.19) 16.59 (8.32) 14.27 (8.87) 0.295 
Serum alkaline 
posphatase 
80.28 (19.18) 81.43 (21.08) 85.58 (30.10) 0.396 
 
Comparative analysis between the subject with normal BMD and abnormal BMD 
group at spine in respect to serum prolactine, calcium, Vitamin D, serum Alk 
phosphatase did not yield significant difference.  
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Table 10: serum prolactin and vitamin D levels compared across the abnormal 
and normal BMD groups  
 
 
Variables N=65 
Abnormal 
BMD N=26 
spine 
Normal 
BMD N=39 
in neck of 
the femur 
P value 
Odd ratio 
with CI 
with risk 
Hyperprolactinemia 52 (81.5%) 23 (44.2%) 29 (55.8%) 
Normal 12 (18.5%) 06 (50.0%) 06 (50.0%) 
0.790 
0.79(0.226-
2.788) 
Vitamin D deficient 
group 
20 (32.8%) 10 (35.7%) 10 (30.3%) 
Vitamin D non-
deficient 
41 (67.2%) 18 (64.3%) 23 (69.7%) 
0.654 
0.783 
(0.268 -
2.286) 
 
 
Comparative analysis between the subject with normal BMD and abnormal BMD 
group at spine in respect to hyperprolactinemia and serum vitamin levels did not yield 
significant difference.  
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Prevalence of gonadal dysfunction 
 
 
Of the 65 subjects, 22 (33.8%) had either amenorrhea or erectile dysfunction. 8 of 33 
females (24.2%) reported amenorrhea and 14 of 32 males (43.8) had erectile 
dysfunction.  
 
On comparing report of either erectile dysfunction or amenorrhea with bone mineral 
density changes at lumbar spine, a statistically significant difference was seen. The 
odds ratio was 3.71 with CI of 1.23-11.24. 
 
Table 11: sexual dysfunction compared in both normal and abnormal BMD at 
lumbar spine 
 
Variable Sub groups Normal BMD spine 
Abnormal 
BMD spine 
P 
value OR 
ED/amenorrhea  
Yes: 21(32.8%) 
 No: 43(67.2%) 
7 (33.3%) 
28 (65.1%) 
14 (66.6%) 
15 (34.9%) 
0.016 
3.71 (1.23-
11.24) 
Amen. in female 
Yes: 8 (25.0%) 
No: 24 (75.0%) 
4 (50.0%) 
16 (66.7%) 
4 (50.0%) 
8 (33.3%) 
0.399 
2.0 (0.39-
10.156) 
ED in male 
Yes: 13 
(40.6%) 
 No: 19 
(60.4%)  
3 (23.1%) 
12 (63.2%) 
10(6.9%) 
7 (36.8%) 
0.026  
5.71 (1.16-
28.07) 
 
A sub group analysis across gender groups in relation to BMD changes at spine was 
carried out.  
Lowered BMD did not correlate with amenorrhea in women p=0.399 and OR 2.0 (CI: 
394-10.156).  
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Among men, ED is significantly related to BMD changes at lumbar spine p 0.026 and 
OR 5.71(1.16-28.07)   
 
Serum Vitamin D and relationship with other factors: 
 
 
Table 12: deficient and non deficient vitamin level compared across other 
variables 
 
 
 
Variables Sub groups 
Normal/insuf 
Vit. D 
Vitamin D 
deficient 
P 
value 
OR CI 
Gender 
Male 31(50%) 
Female 31 (50%) 
18(58.1%) 
24(77.4%) 
13 (41.9%) 
07 (22.6%) 
0.103 
2.47 (0.821-
7.46) 
BMI 
Normal 27 (53.4%) 
Over weight / obesity 
31(46.6%) 
19 (70.4%) 
21 (67.7%) 
08 (29.6%) 
10 (32.3%) 
0.829 
1.13(0.37-
3.46) 
ED /Ame- 
norrhea  
No 40 (64.5%) 
Yes 22 (35.5%) 
29 (72.5%) 
13 (59.1%) 
11 (27.5%) 
09 (40.9%) 
0.280 
0.55(0.18-
1.64) 
Dose of 
Risperidone 
2-4mg 
4.5-10mg 
26(78.8%) 
16(55.2%) 
07(21.2%) 
13(44.8%) 
0.047 
3.01(0.99-
9.157) 
BMD in 
spine 
Normal BMD 
Abnormal BMD 
23 (69.7%) 
18 (64.3%) 
10 (30.3%) 
10 (35.7%) 
0.786 
0.783 (2.68-
2.28) 
BMD in 
neck 
Abnormal BMD 
Normal BMD 
17(65.4%) 
25(69.4%) 
09 (34.6%) 
11(30.6%) 
0.736 
0.83(0.28-
2.43) 
 
Of the 65 subjects, 90.8% had abnormal serum vitamin D levels. In accordance with the 
WHO guideline, 20(30%) had Vitamin D deficiency and 40(60.8%) had vitamin D 
insufficiency and 3(4.1%) had vitamin D sufficiency.  
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For analysis, they were divided into deficient and not deficient groups. In males the 
prevalence of vitamin D deficiency was 13(41.9%) and in females it was 7 (22.6%). No 
statistical difference was seen when vitamin D deficient group and vitamin D non-
deficient group were compared on the basis of gender, body mass index, erectile 
dysfunction/amenorrhea and abnormal BMD changes in spine and femur neck. 
However, the group on higher dose of Risperidone (>4 mg per day) showed higher risk 
of developing Vitamin D deficiency with a p value of.047 OR 3.01(.99-9.157) in 
comparison to the group receiving. 
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DISCUSSION 
 
Antipsychotic medication and BMD changes 
 
Our data showed that 60% of patients on Risperidone have low bone mineral density 
(osteopenia or osteoporosis). Out of 10 people who have osteoporosis, 80% are males 
and 20% are females. The remaining 23 have osteopenia. This is a high prevalence, 
given the mean age (29.6years, SD 6.56) and the fact that these are ambulatory patients, 
with the majority having some form of productive occupation.  
 
The prevalence found by our study is similar to the finding of the other studies, in non-
Indian populations.  
 
In a study on psychiatric in-patients, bone mineral density in the lumbar spine and in 
the femoral neck showed that significant numbers of patients, especially male patients, 
had a remarkable decrease in bone mineral density when compared with age- and sex-
matched normal data. These results may be related to low levels of gonadal hormones, 
especially in male subjects (Halbreich et al). Wyszogrodzka et al demonstrated that 
patients with schizophrenia suffered from a lower mean bone mineral density in 
comparison to the control group. However, both these studies were conducted on 
inpatients on a psychiatric ward. There is no data on Indian patients. 
 
The normative standard used is based on Caucasian data, as there is limited Indian 
normative data. Indian adult population has been found to have low bone mineral 
density. In a study on healthy army recruits, with mean age of 25 years, Tandon showed 
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that 35-50 % of the men (N=20) and 14-32% women (N=22) had BMD abnormalities 
with an additional 10% of men having osteoporosis of the lumbar spine.  
It is possible that normative data derived from Caucasian populations is inapplicable in 
our population, leading to an overestimate of BMD deficiency in our study population. 
Unfortunately, there are no established norms for BMD in healthy Indians. 
 
Hyperprolactemia and BMD changes  
 
88.5% of our subjects who had decreased BMD at either neck of femur or lumbar 
spine, or both, had hyperprolactinemia.  
 
Our study also showed an inverse relationship between prolactin level and BMC (bone 
mineral content) at neck of the femur. 
 
Abraham et al. (2003) reported an inverse relationship between prolactin level and 
bone mass in patients receiving antipsychotic medications. Other studies (Hummer et 
al, 2005; Halbreich et al, 1995) have found a similar relationship. However, these have 
been looked at as continuous variables, without categorization into hyper or 
hypoprolactinemic states. 
 
Thus patients on prolactin raising antipsychotic medication need to be screened for 
hyperprolactinemia and other factors, which can decrease BMD. Patients with 
hyperprolactinemia should be investigated further in order to monitor BMD changes. 
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 Antipsychotic induced hyperprolactinemia 
 
In our study, 84% of women and 78.8% of men, have hyperprolactinemia. In a recent 
study approximately 60% of women and 40% of men treated with a prolactin-raising 
antipsychotic had a prolactin level above the upper limit of the normal range (Haddad 
and Wieck, 2004). Our finding of hyperprolactinemia in female is comparable to the 
findings of the other studies. But, in males prevalence of hyperprolactinemia is almost 
double that in available literature. Such a high prevalence of hyperprolactinemia in 
Indian male psychiatric population needs to be further researched.  
 
81% subjects had hyperprolactinemia, This is similar to that of Wong et al, 2007, who 
found out that patients on Risperidone had the highest level of plasma prolactin, as 
compared to those on typical antipsychotic medication.  
 
Those with hyperprolactinemia did not differ from the non-prolactin raised group in 
clinical parameters and the other biochemical factors measured. 
 
Hyperprolactinemia is an adverse effect of antipsychotic medication that has been 
underinvestigated by clinicians and researchers. Risperidone, in comparison to other 
atypicals commonly used, is more likely to cause hyperprolactinemia. This effect needs 
to taken seriously and investigated further.  
 
No published data is available so far for the Indian population.  
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Antipsychotic induced menstrual irregularities and hyperprolactinemia 
 
 
Sixty percent of women subjects, with a mean age of 30 years, had menstrual related 
abnormalities. 24% had amenorrhea and 38% had delayed menstruation. All women 
who developed amenorrhea had hyperprolactinemia.  
 
Existing data suggests that irregular cycles and  galactorrhoea are common, but that 
clinicians underestimate the prevalence. For example, well conducted studies of women 
treated with conventional antipsychotics have reported prevalence rates of 
approximately 45% for oligomenorrhoea / amenorrhea and 19% for galactorrhoea.  
 
An illness-related under-function of the hypothalamic-pituitary-gonadal axis in female 
patients with schizophrenia may also contribute to menstrual irregularities.  
 
Also, there is evidence in literature to show that baseline menstrual problems get 
worsened and that galactorrhea or gynecomastia manifest only after exposure to 
antipsychotic medication (Kohen et al, 2008). 
 
However we did not elicit information regarding galactorrhea. This must be done in 
future studies.  
 
Biller et al showed that the duration of amenorrhea was positively associated with 
severity of BMD loss. Biller et al., 1991 showed that forty-two percent of 
hyperprolactinemic women who remained amenorrhic for a period of 1.7(SD 0.2) years 
exhibited BMD loss more than two standard deviations below the control mean. 
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Hyperprolactinemic hypogonadal women with secondary amenorrhea resulting from 
low estrogen production were found to have significantly lower BMD than 
hyperprolactinemia women who maintained sufficient estrogen levels to retain menses.   
 
This suggests that women on Risperidone, who develop amenorrhea, are at high risk for 
lowered BMD and possibly for fractures.  
 
The present study has not assessed the duration of amenorrhea and its relation ship with 
changes in BMD 
 
Sexual dysfunction and antipsychotic medication 
 
Forty four percent of males with mean age of 28.84 (6.59) reported erectile dysfunction 
In a study by Ghadirian et al (1982), among out-patients with schizophrenia, 54% of 
men and 30% of women reported sexual dysfunction. Under reporting of sexual 
dysfunction in our study is possible. Reasons include lack of extensive questionnaire, 
culture specific factors and stigma related issues.  
 
Studies show that psychiatric patients rated drug-induced sexual dysfunction as more 
‘bothersome’ than most psychiatric symptoms of their illness (Finn et al, 1990). 
 
Knegtering et al reported a study to comparing sexual side effects of prolactin rising 
antipsychotic medication with those on non-prolactin rising ones. Results showed that 
prolactin raising antipsychotic induced sexual side effects were significantly more as 
compared to prolactin sparing antipsychotic medication. (Knegtering et al, 2008). 
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The presence of ED was significantly associated with impairment in BMD. The report 
of ED should alert the clinician to evaluate BMD. 
     
Vitamin D and chronic mental illness 
 
Our study on patients with on long term Risperidone showed that more than 90 % had 
either vitamin deficiency or insufficiency. 30% were deficient in Vitamin D (<10 
ng/mL). It is alarming to note that 30% of ambulatory psychotic out patients in their 
maintenance phase of treatment, with a mean age of 30 had significant vitamin D 
deficiency. Vitamin D deficient patients received a significantly higher dose of 
Risperidone, and this association has to be studied in larger sample size. 
 
A few studies have evaluated the magnitude of vitamin D deficiency in patients on 
long-term antipsychotic medication.  
 
Tiangga E et al   has studied the prevalence of vitamin D deficiency in a group of male 
psychiatric in-patients and observed that vitamin D deficiency was mostly associated 
with black and minority ethnic background suggesting that that the psychiatric patients 
may be at risk for Vitamin D deficiency. Poor nutrition and reduced duration of 
exposure to sunlight have been postulated as possible mechanisms responsible for a 
vitamin D3 deficiency in patients with schizophrenia. 
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Vitamin D therapy is recommended clinical practice in patients suffering from a 
decrease of bone mineral density. It is cheap, easily available and dosing regimen is 
simple. 
 
Our finding of a relationship between low vitamin D levels and reduced bone mineral 
density resulted from an exploratory analysis and therefore needs to be replicated with 
prior hypothesis testing 
 
It raises the possibility that prophylactic addition of vitamin D to the treatment of 
patients with antipsychotics could reduce the risk of loss of bone mineral density. 
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STRENGTHS 
 
 
1. Risperidone is a widely used antipsychotic. Schizophrenia and other chronic 
psychoses are conditions that manifest in early adulthood, and often need life 
long maintenance treatment. There is no Indian data on the effect on bone 
mineral density, its long-term consequences and its management. 
  
2. Sample size was calculated based on an a priori hypothesis. 
 
3. Multiple factors involving the outcomes of interest were assessed in order to 
reduce bias through confounders. 
 
4. The study addresses a clinically relevant issue.  
 
5. DXA scans are expensive. The facility for this test is not easily available. 
Significantly lowered BMD values correlate with reports of erectile dysfunction 
in men. In a resource poor setting, this clinical information has potential as a 
screening measure to identify those at greater risk for osteopenia or 
osteoporosis.
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LIMITATIONS 
 
 
1. There was no matched healthy adult control group for comparison of parameters 
measured. 
 
2. Study subjects had heterogeneous diagnoses. 
 
3. Other factors influencing Vitamin D levels, such as extent of direct sun light 
exposure, levels of physical activity and dietary habits of our subjects, were not 
assessed. 
 
4. Sexual dysfunction is a sensitive area for assessment. Given the cross sectional 
nature of the study, and the gender of the investigator, this area were assessed 
only in men. 
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CONCLUSION 
 
 
1. This hospital based study of patients receiving maintenance Risperidone for a 
minimum of one year showed a 50% prevalence of abnormal bone mineral 
density. 10 (15.4 %) had osteoporosis, and 23 (35.4%) had ostepenia. The mean 
age was only 29.4 (6.56) years.  
 
2. Sixty percent of women had menstrual irregularities and all women with 
amenorrhea were hyperprolactinemic. 
 
3. 44% of the men reported erectile dysfunction. ED was more significantly 
associated with changes in BMD.  
 
4. Thirty percent of the subjects had severe vitamin D deficiency. The direction of 
causality, if any, and its possible therapeutic potential to reverse or delay this 
process, remains to be explored. 
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INFORMATION FORM 
 
 
Dear Patient, 
 
I am Dr Jayaprakash and I am doing a study. This study is about side effects of the 
medicine that your doctor is prescribing for you – Risperidone. All medicines have side 
effects, and some studies abroad have shown that Risperidone may cause some 
weakness in the bones, similar to what happens in older age. We do not know if this 
happens in Indian patients. I would like to get some knowledge about this. To do this I 
need to test people like yourself – who have an illness and have to take this medicine. 
To do this I need to ask you some questions about your health and body activities, 
illness and treatment. Whatever you tell me will be kept anonymous and confidential.  
To study the bones, a special scan has to be done. The scan machine is in CMC 
hospital. If you agree to taking part in the study, I will make an appointment for this 
test. You will not be asked to pay anything. On the day of the exam you may eat 
normally. You must reach the scan department 15 minutes before the schedule time. 
The procedure will take around 20 minutes. No anesthesia, medicine or injection is 
required. This scan is called DEXA bone densitometry.  
During the scan X-ray will be used to take a picture of the bone. Rays used are less than 
one-tenth the dose of a standard chest X-ray. The amount of radiation used is extremely 
small—less than one-tenth the dose of a standard chest x-ray. Large amounts of 
radiation can harm the body. To the best of our knowledge, the radiation given in the 
scan is unlikely to harm you.  
This test will tell us if your bones are weak. 
 
We will be doing some of the blood tests, which we usually do not do regularly. For 
this study we would be doing these fasting blood tests for better understanding of the 
factors related to weakness in the bones if at all present.    
 
You are invited to be part of this study.  We will give you a copy of this information for 
you to keep. I will be happy to answer any doubts or questions you have. 
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Taking part in this study will not affect your treatment in any way. If you do not wish 
to take part, you will continue with treatment as usual. Even if you agree to take part, 
you can change your mind at any time and leave the study. This will not affect your 
treatment in any way. 
If you wish to take part, I will ask you to sign a form, saying that I have explained all 
the details to you and that you are willing to take part. Even after signing, you may 
change your mind and cancel it at any time.  
The research committee and the ethics committee of the Christian Medical College, 
Vellore, have approved this study.  This means that a group of doctors of this hospital 
have studied this plan and have given permission for me to do this study. 
If you have any doubts, or want additional information, contact any of the following in 
this hospital. We can be contacted at the following address: 
 
*Dr.JP Russell Ravan     Dr.Naveen Thomas  Dr.Deepa Braganza 
Registrar   Assistant Professor  Professor 
 
 
Dept. of Psychiatry 
Christian Medical College 
Bagayam,Vellore-632 002. 
Tamilnadu 
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CONSENT FORM 
 
 
Dr Jayaprakash has explained to me in detail about the study and risks involve 
secondary to radiation during DEXA Scan and blood tests. I understand that taking part 
may not benefit me directly.  My treatment will not be affected if I refuse to participate 
in the study. I can withdraw consent at any point without having to say why. 
 
 I, …………………………………………….., hereby consent to participate in the 
study. 
Date……………………         
     
Name ……………………………………………………. 
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APPENDIX II 
 
Clinical Data sheet 
 
Date of Assessment…………… 
 
Socio demographic profile 
 
 
Hospital Number                    ……………………………………… 
 
Age                         ………………………………………… 
 
Gender                    …….. ………………………………… 
 
Marital Status    …………………………………………  
 
Religion                    ………………………………………… 
 
 
Whether patient is employed   …………..……………………... 
 
Height………………………Weight……………………  
 
Disease and Diagnostic profile 
 
ICD 10 Diagnosis  ……………………………………… 
 
Co-morbid Axis I Diagnosis …………………………. 
 
Substance abuse  ………………………………………. 
 
Any co-morbid medical condition …………………….. 
 
 
Other medication taken with Risperidone      …………. ……………. 
 
Age at which illness began               ……...……………………………  
 
Dose of Risperidone   …………………………. 
 
Duration of untreated psychosis                    ………………………. 
 
Duration of treatment with Risperidone          ………………………. 
 
Is there any expose to other antipsychotic treatment ………. If yes 
 
Name and duration of other antipsychotic drug……………………… 
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Sexual or menstrual functioning profile  
 
Base line sexual functioning …………………………………………….. 
 
Sexual dysfunction on treatment   Y/ N         Duration               
 
If yes, Loss of Libido / ED/ PME    ………………………………………. 
 
Menstrual function before onset of illness ……………………………… 
 
Menstrual function before commencement of Risperidon …………….. 
 
Period of amenorrhea on Risperidone    ………………………………… 
 
Height ……….. 
 
Weight ………….. 
 
Circumference at the level of umbilicus …………………….. 
 
Whether the patient can stand unsupported from squatting position ……………… 
 
 
 
 
